Glutamate receptor ionotropic, NMDA 1 (NR1) (NR1)

The NMDA receptor NR1 glycine binding site, also known as the glycine-B site, is a critical regulatory domain located on the Glutamate receptor ionotropic, NMDA 1 (NR1 or GluN1) subunit of the N-methyl-D-aspartate (NMDA) receptor complex [UniProt, P35431]. Unlike most other ligand-gated ion channels, the NMDA receptor requires the simultaneous binding of two distinct co-agonists for activation: glutamate at the NR2 subunit and glycine (or D-serine) at the NR1 subunit [StatPearls, NBK526134]. This dual-agonist requirement makes the glycine binding site a unique "gatekeeper" for receptor function, which is essential for synaptic plasticity, long-term potentiation, and excitatory neurotransmission [PubMed, 12183634]. Dysfunction of NMDA receptor signaling is implicated in a wide range of neurological and psychiatric conditions, including schizophrenia, Alzheimer's disease, and chronic pain [PubMed, 11918971]. Therapeutic strategies targeting this site include the use of partial agonists like D-cycloserine and rapastinel to enhance NMDA receptor function in cognitive disorders and schizophrenia, as well as antagonists like gavestinel to prevent excitotoxic damage in stroke or to alleviate neuropathic pain [PubMed, 12467589]. However, modulating this site presents challenges, as excessive activation can lead to neurotoxicity, while potent antagonism may cause psychotomimetic side effects or sedation [PubMed, 10523971]. Research continues to explore the glycine site as a target for novel antidepressants and cognitive enhancers with improved safety profiles compared to non-competitive channel blockers [PubMed, 26935058].

Other names

GluN1GRIN1NMDA receptor subunit 1Glycine-B siteGlycine co-agonist siteNMDA receptor NR1 subunit

Drugs targeting the NMDA receptor NR1 glycine binding site act as co-agonists, partial agonists, or competitive antagonists to modulate the opening of the NMDA receptor's ion channel, thereby regulating calcium influx and downstream signaling pathways [PubMed, 12183634].